Compare Noble Corporation plc (NE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Recursion Pharmaceuticals Inc — how do they compare? Noble Corporation plc trades at $42.53 (market cap $6.48B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Noble Corporation plc is far larger — about 4.2× Recursion Pharmaceuticals Inc's market cap, and Noble Corporation plc pays a 4.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NE | RXRX | |
|---|---|---|
Market Cap | $6.48B | $1.53B |
Sector | Technology | Health |
52-Week High | $54.37 | $6.79 |
52-Week Low | $25.70 | $2.84 |
Enterprise Value | $7.73B | $946.50M |
Dividend Yield | 4.93% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
